Press

Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor Celia Morgan

Aug 26 • 3 min read

Quick Take: The study will be led by Dr. Celia Morgan, a professor of psychopharmacology at the University of Exeter. Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (Awakn), a biotechnology company developing and delivering psychedelic medicine to better treat Addiction, announced today that it has received ethical committee approval and has initiated…

PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to Evaluate DMT in a Comparative Clinical Study

Aug 26 • 5 min read

Quick Take: The clinical trial agreement will study the acute and enduring psychological and neural effects of DMT. PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased…

Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida

Aug 25 • 3 min read

Quick Take: The training, conducted by Fluence, represents a best-in-class approach for psychotherapy that will accompany the administration of psilocybin for overeating disorders Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today it has completed the training of psychotherapists…

MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders

Aug 24 • 3 min read

Quick Take: Mindmed will be collaborating with Forian to use real-world evidence information to help better make decisions for psychiatric patients. Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a leading biotech company developing psychedelic-inspired therapies, has agreed to work with Forian Inc. (NASDAQ: FORA), a leading provider of evidence-based support for more comprehensive clinical…

Mindset Pharma Broadens its IP Portfolio by Filing U.S. Provisional Patent Extending its DMT and 5-MeO-DMT Inspired Psychedelic Drug Candidates

Aug 24 • 2 min read

Quick Take: Mindset has filed a patent to include a number of DMT analog compounds. These DMT analogs have shown promising pharmacological characteristics according to Mindset’s CEO James Lanthier. Mindset Pharma Inc. (CSE: MSET), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441